APA

Giles F. J., Kantarjian H. M., Kornblau S. M., Thomas D. A., Garcia-Manero G., Waddelow T. A., David C. L., Phan A. T., Colburn D. E., Rashid A. & Estey E. H. (20010809). Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. : Cancer.

Chicago

Giles F J, Kantarjian H M, Kornblau S M, Thomas D A, Garcia-Manero G, Waddelow T A, David C L, Phan A T, Colburn D E, Rashid A and Estey E H. 20010809. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. : Cancer.

Harvard

Giles F. J., Kantarjian H. M., Kornblau S. M., Thomas D. A., Garcia-Manero G., Waddelow T. A., David C. L., Phan A. T., Colburn D. E., Rashid A. and Estey E. H. (20010809). Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. : Cancer.

MLA

Giles F J, Kantarjian H M, Kornblau S M, Thomas D A, Garcia-Manero G, Waddelow T A, David C L, Phan A T, Colburn D E, Rashid A and Estey E H. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. : Cancer. 20010809.